DIPG-05. CHARACTERIZATION OF THE EFFECTS OF H3K27M VARIANTS ON THE DNA-DAMAGE RESPONSE AND TUMOR EVOLUTION IN DIFFUSE MIDLINE GLIOMA

Abstract

Abstract Diffuse midline gliomas (DMGs) are universally-fatal pediatric brain tumors driven by K27M alterations in histone 3 (H3K27M). Histone 3 is encoded by several variants, including the canonical H3.1, and H3.3 which replaces H3.1 at transcriptionally active and repetitive genomic regions. Both H3.3K27M and H3.1K27M are present as driver events in DMGs and recent single-cell-RNA and whole-genome sequencing experiments have demonstrated that they define distinct subsets of disease, with varying secondary genetic alterations and different gene-expression patterns. The cause of the divergence in routes of tumor evolution between these subsets remains an open question. Previous work by our group has shown that H3.3K27M DMGs show greater genomic instability than H3.1K27M tumors – with a greater number and higher complexity of genomic structural variants resulting from errors in double-stranded DNA break repair. This raises the possibility that histone variants differentially influence the generation of, or response to, DNA breaks. Here we present an early-stage project that aims to investigate whether H3K27M variants are sufficient to produce differences in genomic instability and in directing the path of tumor evolution. Using isogenic cell-line models expressing H3.1K27M or H3.3K27M, we aim to characterize whether H3K27M variants produce varying levels of replicative stress and P53 activation, leading to varying selective pressures for P53 loss. In turn, we seek to demonstrate that loss of P53 produces a greater growth advantage in H3.3K27M cells, and that P53 loss leads to increased tolerance of genomic instability in DMG models. Together, these experiments seek to provide new insight on the mechanisms of divergence between H3.1K27M and H3.3K27M-driven DMGs, and a better understanding of the sources of genomic instability in DMGs. Given that ionizing radiation remains the only approved treatment modality for DMGs, a greater understanding of DMG response to DNA-damage is critical to improving therapeutic outcomes.